4//SEC Filing
Gergel Ivan P. 4
Accession 0001209191-17-061590
CIK 0000906709other
Filed
Nov 16, 7:00 PM ET
Accepted
Nov 17, 6:03 PM ET
Size
11.5 KB
Accession
0001209191-17-061590
Insider Transaction Report
Form 4
Gergel Ivan P.
SVP & Chief Medical Officer
Transactions
- Award
Stock Option
2017-11-15+50,000→ 50,000 totalExercise: $14.41Exp: 2024-12-12→ Common Stock (50,000 underlying) - Award
Common Stock
2017-11-15+20,000→ 61,575 total - Disposition to Issuer
Common Stock
2017-11-16$44.23/sh−5,022$222,123→ 56,553 total
Footnotes (7)
- [F1]Represents restricted stock units ("RSUs"), convertible on a one-for-one basis into shares of Common Stock of the Company. These RSUs, at the time of their grant on December 13, 2016, were subject to both performance-based and time-based vesting requirements. On November 15, 2017, the performance-based condition vesting was satisfied. The time-based vesting is on a quarterly pro-rata basis over a period of three (3) years from the date of grant.
- [F2]These restricted stock units ("RSUs") were granted on December 13, 2016 and the performance-based vesting requirement for these RSUs was satisfied on November 15, 2017 upon the Compensation Committee's certification of the successful acceptance of the New Drug Application by the FDA for Ciprofloxacin Dry Powder Inhalation (Cipro DPI).
- [F3]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
- [F4]This transaction was executed in multiple trades at prices ranging from $41.98 to $45.47. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
- [F5]These options, at the time of their grant were subject to both performance-based and time-based vesting requirements. On November 15, 2017, the performance-based condition vesting was satisfied. The time-based vesting is on a monthly pro-rata basis over a period of four years from the grant date (December 13, 2016).
- [F6]These stock options were granted on December 13, 2016 and the performance-based vesting requirement for these stock options was satisfied on November 15, 2017 upon the Compensation Committee's certification of the successful acceptance of the New Drug Application by the FDA for Ciprofloxacin Dry Powder Inhalation (Cipro CPI).
- [F7]This stock option vests on a monthly pro-rata basis over a period of four years from the grant date.
Documents
Issuer
NEKTAR THERAPEUTICS
CIK 0000906709
Entity typeother
Related Parties
1- filerCIK 0001328288
Filing Metadata
- Form type
- 4
- Filed
- Nov 16, 7:00 PM ET
- Accepted
- Nov 17, 6:03 PM ET
- Size
- 11.5 KB